Dry Powder Inhaler (DPI)

Dry Powder Inhaler (DPI) refers to an inhalation delivery device that administers medication as a dry powder formulation into the lungs, commonly used for asthma, chronic obstructive pulmonary disease, and other respiratory conditions. DPIs rely on patient inhalation effort to disperse and deliver particles to the respiratory tract, requiring careful formulation and device engineering to achieve consistent dosing and deep lung deposition.

The pharmaceutical industry develops DPI products balancing formulation stability, particle engineering, device usability, and performance across diverse patient populations. Powder properties including particle size distribution, flowability, and moisture sensitivity strongly influence delivery efficiency. Device design affects dose consistency, resistance profiles, and user technique requirements, with human factor studies supporting patient safety and usability. Regulatory submissions include device performance testing, in vitro aerodynamic characterisation, and clinical evidence supporting efficacy and safety. As respiratory therapeutics expand and interest grows in pulmonary delivery of biologics and vaccines, DPI technologies continue evolving through improved formulation science, advanced devices, and patient-centric design approaches.